Ann Lab Med.  2023 Jul;43(4):323-324. 10.3343/alm.2023.43.4.323.

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia

• Kim SY
• Huh HJ

• KMID: 2551948
• DOI: http://doi.org/10.3343/alm.2023.43.4.323

Reference

1. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. 2018; Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 131:1275–91. DOI: 10.1182/blood-2017-09-801498. PMID: 29330221. PMCID: PMC5865231.

2. Panuzzo C, Jovanovski A, Ali MS, Cilloni D, Pergolizzi B. 2022; Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. J Clin Med. 11:483. DOI: 10.3390/jcm11030483. PMID: 35159934. PMCID: PMC8836582.

3. Wheeler FC, Kim AS, Mosse CA, Shaver AC, Yenamandra A, Seegmiller AC. 2018; Limited utility of fluorescence in situ hybridization for recurrent abnormalities in acute myeloid leukemia at diagnosis and follow-up. Am J Clin Pathol. 149:418–24. DOI: 10.1093/ajcp/aqy002. PMID: 29538617. PMCID: PMC5888921.

4. Selim AG, Moore AS. 2018; Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions. J Mol Diagn. 20:389–97. DOI: 10.1016/j.jmoldx.2018.03.005. PMID: 29689379.

5. Chung HJ, Hur M, Yoon S, Hwang K, Lim HS, Kim H, et al. 2020; Performance evaluation of the QXDx BCR-ABL %IS droplet digital PCR assay. Ann Lab Med. 40:72–5. DOI: 10.3343/alm.2020.40.1.72. PMID: 31432643. PMCID: PMC6713652.

6. Kim HY, Yoo IY, Lim DJ, Kim HJ, Kim SH, Yoon SE, et al. 2022; Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med. 42:558–65. DOI: 10.3343/alm.2022.42.5.558. PMID: 35470273. PMCID: PMC9057816.

7. Kim H, Yun JW, Lee ST, Kim HJ, Kim SH, Kim JW, et al. 2019; Korean Society for Genetic Diagnostics guidelines for validation of next-generation sequencing-based somatic variant detection in hematologic malignancies. Ann Lab Med. 39:515–23. DOI: 10.3343/alm.2019.39.6.515. PMID: 31240878. PMCID: PMC6660343.

8. Zhong Y, Xu F, Wu J, Schubert J, Li MM. 2021; Application of next generation sequencing in laboratory medicine. Ann Lab Med. 41:25–43. DOI: 10.3343/alm.2021.41.1.25. PMID: 32829577. PMCID: PMC7443516.

9. Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D. 2014; Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol. 27:1438–46. DOI: 10.1038/modpathol.2014.57. PMID: 24743218. PMCID: PMC4201902.

10. Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. 2018; A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2:825–31. DOI: 10.1182/bloodadvances.2018015925. PMID: 29643105. PMCID: PMC5916006.

11. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. 2016; Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–21. DOI: 10.1056/NEJMoa1516192. PMID: 27276561. PMCID: PMC4979995.

12. Kim JJ, Jang JE, Lee HA, Park MR, Kook HW, Lee ST, et al. 2023; Development of a next-generation sequencing-based gene panel test to detect measurable residual disease in acute myeloid leukemia. Ann Lab Med. 43:328–40. DOI: 10.3343/alm.2023.43.4.328. PMID: 36843401.